Evaluation of diagnostic strategy for Primary Immunodeficiency Disorders (PID) with antibody deficiency in adult patients.

Dear Sir/Madam,

We invite you to participate in a medical program aimed at improving the recognition of Primary Immunodeficiency Disorders with antibody deficiency (PID). The GepPard program includes performing a diagnosis that confirms or excludes PID with antibody deficiency based on standard medical procedures.

To begin the study, it is necessary to conclude an online agreement, so please register and follow the information appearing on the computer screen.

After successful registration and signing of the electronic agreement, please log in with the data obtained during the account creation process.

BioStat® company ensures a smooth
course of the study and data analysis.

Any questions should be directed to the organizer's office.

BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
Tel: +48 666 069 814
Email: [email protected]

Study sponsor

Takeda Pharma sp. z o.o.
Prosta 68, 00-838 Warsaw
Tel: +48 22 608 13 00/01
Fax: +48 22 608 13 03

Please log in with the data received after signing the online agreement.

The material for doctors, prepared at the initiative and sponsored by Takeda.
Copyright © 2021 Takeda Pharmaceutical Company Limited. All rights reserved.
All trademarks are the property of their rightful owners.

VV-MEDMAT-37388, 01/2021